Menu
Recruiting NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase I / Phase II Interventional Non-small Cell Lung Cancer Histiocytic Neoplasm Histiocytosis BRAF Gene Mutation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab.
Who it may be relevant to
Registry conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Denmark, Hong Kong, Japan, United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Overview

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC with KRAS and/or BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

Interventions

  • Drug S241656
    RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
  • Drug FOLFOX6/FOLFOX7
    Used as a combination therapy and administered intravenously
  • Drug FOLFIRI
    Used as a combination therapy and administered intravenously
  • Drug Cetuximab
    Used as a combination therapy and administered intravenously
  • Drug Panitumumab
    Used as a combination therapy and administered intravenously
  • Drug Gemcitabine
    Used as a combination therapy and administered intravenously
  • Drug Nab-paclitaxel
    Used as a combination therapy and administered intravenously

Primary outcome measures

  • Dose Escalation: Incidence of dose-limiting toxicities (DLTs) [Time frame: The first 28-day cycle (Cycle 1)]
  • Dose Escalation: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Time frame: Through study completion, approximately 5 years]
  • Dose Optimization/Expansion: Objective response (OR) [Time frame: Through study completion, approximately 5 years]
Secondary outcome measures (12)
  • Dose Escalation/Expansion: Incidence and severity of treatment-emergent adverse events (TEAEs) [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Maximum plasma concentration (Cmax) of S241656 and its metabolite S243796 [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Time of maximum plasma concentration (Tmax) of S241656 and its metabolite S243796 [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Area under the plasma drug concentration-time curve (AUC) of S241656 and its metabolite S243796 [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Half-life (t1/2) of S241656 and its metabolite S243796 [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation: Objective response (OR) [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Disease Control (DC) [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Clinical Benefit (CB) [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Duration of response (DOR) [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Time to response (TTR) [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Progression-free Survival (PFS) [Time frame: Through study completion, approximately 5 years]
  • Dose Escalation/Optimization/Expansion: Overall survival (OS) [Time frame: Through study completion, approximately 5 years]

Eligibility criteria

Inclusion criteria

  • Life expectancy of ≥ 12 weeks in the opinion of the investigator.
  • Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations.
  • Adequate bone marrow and organ function.
  • Recovered from toxicity to prior anti-cancer therapy.

Part 1 Dose Escalation cohort ONLY:

  • Part 1A: Advanced/metastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations
  • Part 1B: Advanced/metastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations
  • Part 1C: Advanced/metastatic PDAC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations
  • Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations
  • Part 1E: Other advanced/metastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, CRAF (RAF1) mutations or alterations

Part 2 Dose Optimization and Expansion cohorts ONLY:

  • Part 2A: Advanced/metastatic NSCLC with KRAS non-G12C mutations and/or BRAF mutations
  • Part 2A1: Advanced/metastatic NSCLC with KRAS non-G12C mutations
  • Part 2A2: Advanced/metastatic NSCLC with BRAF mutations
  • Part 2A3: Advanced/metastatic NSCLC with KRAS non-G12C or BRAF mutations or alterations and active CNS metastatic disease
  • Part 2A4: Advanced/metastatic NSCLC with a KRAS G12C mutation
  • Part 2B1: Advanced/metastatic PDAC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations
  • Part 2B2: Advanced/metastatic CRC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations
  • Part 2B3: Advanced/metastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations

Exclusion criteria

  • Cancer that has a known MEK1/2 mutation.
  • Known allergy/hypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination.
  • Any contra-indication, to use of any of the combination chemotherapy or anti-EGFR therapy partners administered as part of this trial.
  • Major surgery within 4 weeks of study entry or planned during study.
  • Ongoing anticancer therapy.
  • Ongoing radiation therapy.
  • Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.
  • Clinically significant cardiovascular disease.
  • Symptomatic spinal cord compression.
  • Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
  • Females who are pregnant or breastfeeding.
  • Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.
  • Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Sequential
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 20 centers
  • Banner Health- MD Anderson Cancer Center — Gilbert
  • The Angeles clinic - A cedars SINAI AFFILIATE — Los Angeles
  • USC Norris Comprehensive Cancer Center — Los Angeles
  • University of California, San Francisco (UCSF) — San Francisco
  • University of Colorado - Aurora Cancer Center — Aurora
  • Yale University School of Medicine - Yale Cancer Center — New Haven
  • Georgetown University Lombardi Cancer Center — Washington D.C.
  • Dana-Farber Cancer Institute — Boston
  • … and 12 more centers
United Kingdom · 3 centers
  • University College London Hospital — London
  • Hammersmith Hospital — London
  • The Christie NHS Foundation Trust — Manchester
Japan · 2 centers
  • Kyoto University Hospital — Kyoto
  • National Cancer Center Hospital — Tokyo
Denmark · 1 center
  • Center for Cancer and Organ Diseases - Rigshospitalet — Copenhagen
Hong Kong · 1 center
  • Queen Mary Hospital — Hong Kong

Identifiers

NCT: NCT05786924 · BDTX-4933-101 · 2025-523474-16-00

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗